Afficher la notice abrégée

Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort

dc.rights.licenseopenen_US
dc.contributor.authorHURAULT-DELARUE, C.
dc.contributor.authorLACROIX, I.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBENARD-LARIBIERE, Anne
dc.contributor.authorMONTASTRUC, J. L.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.contributor.authorDAMASE-MICHEL, C.
dc.date.accessioned2020-06-23T08:41:29Z
dc.date.available2020-06-23T08:41:29Z
dc.date.issued2019-10
dc.identifier.issn1433-8491 (Electronic) 0940-1334 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8097
dc.description.abstractEnBACKGROUND: Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France. METHODS: We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied. RESULTS: During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed. CONCLUSIONS: Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enAntidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort
dc.title.alternativeEur Arch Psychiatry Clin Neuroscien_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00406-018-0906-2en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29804133en_US
bordeaux.journalEuropean Archives of Psychiatry and Clinical Neuroscienceen_US
bordeaux.page841-849en_US
bordeaux.volume269en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209258
hal.version1
hal.date.transferred2021-04-27T08:14:28Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Archives%20of%20Psychiatry%20and%20Clinical%20Neuroscience&rft.date=2019-10&rft.volume=269&rft.issue=7&rft.spage=841-849&rft.epage=841-849&rft.eissn=1433-8491%20(Electronic)%200940-1334%20(Linking)&rft.issn=1433-8491%20(Electronic)%200940-1334%20(Linking)&rft.au=HURAULT-DELARUE,%20C.&LACROIX,%20I.&BENARD-LARIBIERE,%20Anne&MONTASTRUC,%20J.%20L.&PARIENTE,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée